Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin S. Tang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preoperative and anesthetic management of high-risk cardiovascular complications of mediastinal masses: a narrative review

    by Keith Nishihara, Nikitha Reddy, Kevin S. Tang

    The mediastinum is a complex anatomical region that includes the heart, aorta, superior vena cava, trachea, and mainstem bronchi. Mediastinal masses, while relatively uncommon, can cause life-threatening cardiovascular symptoms from mass effect, including cardiac tamponade, superior vena cava syndrome, mediastinal mass syndrome, and right ventricular outflow tract obstruction, requiring prompt identification and management. Currently, there are no guidelines that discuss the optimal management of these cardiovascular complications, and our review aims to address this. A database search in PubMed was conducted from September 2025 to November 2025, including articles related to mediastinal masses and the various cardiovascular complications that can arise. Selected articles were compiled and reviewed to help compose this review. This review aims to outline the incidence and etiology of different mediastinal masses, review the presentation and diagnostic workup, highlight key life-threatening syndromes related to mass effect, and discuss definitive management of these lesions. Given the complexity of the mediastinum and potential for several life-threatening complications without appropriate identification, timely diagnosis is needed to guide management. A multidisciplinary approach is crucial in the stabilization and management of these patients with mediastinal masses and should be considered the standard of care in all patients. This review aims to summarize current literature for the management of cardiovascular complications related to mediastinal masses.

  • Open Access

    Lipid Trajectory Patterns in China

    by Kevin S. Tang

  • Open Access

    Surgical and Transcatheter Tricuspid Valve Interventions: An Electrophysiology-Focused Review

    by Kevin S. Tang, Mark W. Abdelnour, Robert M. Tungate, Christina Mansour, Fabio Sagebin, Antonio H. Frangieh, David M. Donaldson

    Increasing recognition of the clinical impact of isolated tricuspid regurgitation has led to rapid expansion of surgical and transcatheter tricuspid valve interventions. Given the close anatomic relationship between the tricuspid valve and the atrioventricular conduction system, both surgical and transcatheter approaches carry a significant risk of new conduction disturbances and permanent pacemaker implantation. A three-dimensional understanding of the atrioventricular conduction axis is essential to anticipate and mitigate these complications. This review provides a comprehensive overview of conduction system anatomy and physiology in the context of tricuspid valve interventions, highlighting the mechanisms underlying procedure-related conduction abnormalities. We also discuss contemporary management strategies, including approaches to pre-existing transvalvular leads, valve-sparing pacing alternatives, and the evolving role of electrophysiologists within the multidisciplinary heart team.

  • Open Access

    A Look Towards Next Steps

    by Kevin S. Tang, Andy Y. Lee

  • Top Cited Papers
    Open Access

    Frailty and Cardiometabolic Outcomes: A Narrative Review

    by Saam Foroshani, Kevin S. Tang, Nathan D. Wong

    Frailty is a multidimensional state of reduced physiological reserve that is increasingly recognized as a major determinant of outcomes in cardiovascular diseases (CVDs). As populations age and cardiometabolic multimorbidity becomes more prevalent, understanding how frailty interacts with CVD pathology has important implications for risk stratification, clinical decision-making, and patient-centered care. Across diverse cardiovascular conditions and interventions, frailty independently predicts higher risks of mortality, major adverse cardiovascular events (MACE), rehospitalization, procedural complications, functional decline, and reduced quality of life. Shared biological mechanisms—including chronic inflammation, sarcopenia, endothelial dysfunction, and the effects of multimorbidity and polypharmacy—help explain the strong and often bidirectional relationship between frailty and CVD, one that is reported by recent data to be multiplicative as well as additive. Importantly, frailty demonstrates prognostic value beyond traditional risk factors and varies in predictive performance depending on the assessment tool used. Finally, frailty should not be viewed as immutable; evidence shows that appropriate conditioning may slow the decline or even reverse frail or prefrail states. This narrative review aims to synthesize contemporary evidence on frailty definitions and assessment, epidemiology, mechanistic pathways linking frailty with CVD, associated outcomes, prognostic value, and emerging interventions relevant to CVD prevention and management.


  • Open Access

    Beyond the Sum of Their Parts

    by Kevin S. Tang, Wenjun Fan


  • Prevalence and Mortality Trends of Hypertension Subtypes Among US Adults: An Analysis of the National Health and Nutrition Examination Survey

    by Kevin S Tang, Jeffrey E Jones, Wenjun Fan, Nathan D Wong

    BACKGROUND: Hypertension (HTN) has been demonstrated as one of the leading risk factors for development of cardiovascular disease (CVD) and CVD mortality. METHODS: This study examines the prevalence and distribution of HTN subtypes (isolated diastolic hypertension [IDH], isolated systolic hypertension [ISH], and systolic-diastolic hypertension [SDH]) across age, sex, and race/ethnicity per the nationally representative National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020 based on the updated 2017 ACC/AHA HTN definition. We further examined for associations of each subtype with CVD and all-cause mortality using Cox regression analysis. RESULTS: Among US adults, the overall prevalence of HTN is 47.4%. Across increasing age, the prevalence of IDH decreased, ISH increased, and SDH increased and peaked in the 6th decade of life after which SDH prevalence decreased. By age 80, over 80% of persons with HTN demonstrated ISH. A subcohort from NHANES 1999–2008 with follow-up until 2018 showed that ISH and SDH were most strongly associated with increased risk for CVD (HR = 1.18, 95% CI, 1.01–1.38; HR = 1.31, 95% CI, 1.07–1.60, respectively) and all-cause mortality (HR = 1.17, 95% CI, 1.06–1.28; HR = 1.21, 95% CI, 1.08–1.37, respectively). CONCLUSIONS: Our data demonstrate the continuing importance of HTN subtype transitions across age and their differences in predicting future CVD and total mortality.


  • Open Access

    Case Report: A crushing sensation—a rare case of mediastinal germ cell tumor causing cardiac tamponade

    by Kevin S. Tang, Emin Zargarian, Pranav M. Patel

    Cardiac tamponade often presents as external compression of the heart by pericardial fluid, leading to hemodynamic instability, but it can rarely be caused by compression by a solid mass. In this report, we present a case of tamponade-like physiology resulting from a large mediastinal tumor. This is an unusual phenomenon that is rarely described in the literature, and its optimal management remains controversial. This report reviews the clinical considerations for this rare pathophysiology; definitive therapy requires the involvement of a multidisciplinary approach for hemodynamic optimization and mass removal.


  • Open Access

    Shortened Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Contemporary Clinical Review

    by Kevin S Tang, Shoujit Banerjee, George Tang, Pranav M Patel, Antonio H Frangieh

    Percutaneous coronary intervention with stent implantation is an integral aspect of minimally interventional cardiac procedures. The technology and techniques behind stent design and implantation have evolved rapidly over several decades. However, continued discourse remains around optimal peri- and post-interventional management with dual antiplatelet therapy to minimise both major cardiovascular or cerebrovascular events and iatrogenic bleeding risk. Standard guidelines around dual antiplatelet therapy historically recommended long-term dual antiplatelet therapy for 12 months (with consideration for >12 months in certain patients); however, emerging data and generational improvements in the safety of drug-eluting stents have ushered in a new era of short-term therapy to reduce the incidence of major bleeding events. This case review will provide an overview of the current state of guidelines around duration of dual antiplatelet therapy and examine recent updates and continued gaps in existing research.


  • Open Access

    Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention

    by Jeffrey E. Jones, Kevin S. Tang, Ailin Barseghian, Nathan D. Wong

    Over the last half-century, discussions on the exact targets for low-density lipoprotein cholesterol (LDL-C) reduction have evolved towards a more aggressive approach with lower LDL-C targets, particularly for high-risk patients with pre-existing atherosclerotic cardiovascular disease (ASCVD). A wealth of cardiovascular outcome trials have shown the efficacy of statin therapy in general, as well as the incremental impact of high-intensity statin therapy in particular. More recent trials have further demonstrated the impact of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and, most recently, bempedoic acid, on reducing ASCVD outcomes. The availability of these and other newer therapies has prompted clinicians to strive for lower LDL-C targets to address residual ASCVD risk after statin therapy. This paper will provide an overview of the historical trends in lipid management and therapeutics and review the current state of evidence for lower LDL-C targets in clinical guidelines and recommendations.